Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics

FOSTER CITY, Calif. & NEWARK, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) and CymaBay Therapeutics, Inc. (Nasdaq: CBAY) announced today a definitive agreement under which Gilead will acquire CymaBay for $32.50 per share in cash or a total equity value of $4.3 billion. The addition of CymaBay’s investigational lead product candidate,…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks